Efficacy and safety of ospemifene in postmenopausal women with moderate-to-severe vaginal dryness: a phase 3, randomized, double-blind, placebo-controlled, multicenter trial-Reference-Cited by-同舟云学术

Efficacy and safety of ospemifene in postmenopausal women with moderate-to-severe vaginal dryness: a phase 3, randomized, double-blind, placebo-controlled, multicenter trial

Published:2019-01-28 Issue:6 Volume:26 Page:611-621
ISSN:1072-3714
Container-title:Menopause
language:en
Short-container-title:

Author:

Archer David F.,Goldstein Steven R.,Simon James A.,Waldbaum Arthur S.,Sussman Steven A.,Altomare Corrado,Zhu Julie,Yoshida Yuki,Schaffer Sam,Soulban Graziella

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Obstetrics and Gynecology,General Earth and Planetary Sciences,General Environmental Science

Reference21 articles.

1. The 2017 hormone therapy position statement of The North American Menopause Society;Menopause,2017

2. Management of menopausal symptoms. Practice Bulletin No. 141;Obstet Gynecol,2014

3. Incremental direct and indirect costs of untreated vasomotor symptoms;Sarrel;Menopause,2014

4. Prevalence and impact of vaginal symptoms among postmenopausal women;Santoro;J Sex Med,2009

5. Vaginal health in the United States: results from the Vaginal Health: Insights, Views & Attitudes survey;Simon;Menopause,2013

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hormonal Treatments and Vaginal Moisturizers for Genitourinary Syndrome of Menopause;Annals of Internal Medicine;2024-09-10

2. Managing sexual health challenges in breast cancer survivors: A comprehensive review;The Breast;2024-08

3. Ospemifene and vulvovaginal atrophy: an update of the clinical profile for post-menopausal women;Expert Opinion on Pharmacotherapy;2024-07-23

4. Oral lasofoxifene's effects on moderate to severe vaginal atrophy in postmenopausal women: two phase 3, randomized, controlled trials;Menopause;2024-04-23

5. An empowerment model for managing menopause;The Lancet;2024-03